NCT03046459View on ClinicalTrials.gov

A First-in-Human Study of BNZ132-1-40

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

June 5, 2017

Study Completion Date

June 5, 2017

Conditions
Healthy
Interventions
BIOLOGICAL

BNZ132-1-40

pegylated peptide inhibiting IL-2, IL-9 and IL-15

Trial Locations (1)

85283

Celerion, Phoenix

Sponsors

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Bioniz Therapeutics

INDUSTRY